Tuesday, April 30, 2019

Glenmark launches cheaper SGLT2 inhibitor class of anti-diabetes drug in India

Glenmark launches cheaper SGLT2 inhibitor class of anti-diabetes drug in India The drug, generically called as Remogliflozin etabonate, is used in the treatment of type-2 diabetes mellitus in adults.

from Moneycontrol Business News http://bit.ly/2WilzOg

No comments:

Post a Comment

LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally

A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...